200,000 ft²
200,000 ft²
capacity for advanced therapy process development
and cGMP manufacturing
capacity for advanced therapy process development
and cGMP manufacturing
capacity for advanced therapy process development
and cGMP manufacturing
capacity for advanced therapy process development
and cGMP manufacturing
of Class B and C Clean Rooms
of Class B and C Clean Rooms
Over
Over
experts in gene & cell therapy areas
experts in gene & cell therapy areas
state-of-the-art cGMP
production suites
state-of-the-art cGMP
production suites
At Porton Advanced Solutions, we are committed to accelerating delivery of life-changing advanced therapies to patients. As a Cell and Gene Therapy CDMO company, we provide end-to-end biopharma solutions and services to our clients throughout the development and commercialization of their therapeutics.
Our goal is to improve availability and commercial viability of these life-changing treatments by accelerating therapeutic development through our unique, innovative approach.
Porton Advanced Solutions is a subsidiary of the leading CDMO Porton Pharma Solutions. Porton Pharma Solutions is globally recognized and trusted for its process innovation, supply chain performance and compliance with global quality and EHS standards.
Our clients include a wide range of biotech and pharmaceutical companies, academic research institutes, and hospitals, each with unique needs spanning across discovery research, drug development, different clinical phases, and commercialization.
Our innovative, integrated approach enables us to respond to the full needs of each individual customer.
We provide end-to-end biopharma solutions according to each client’s needs across multiple therapeutic platforms.
We have been investing heavily in platform development across the Cell and Gene Therapy (C>) and Chemistry, Manufacturing, and Control (CMC) spaces.
Our dedicated process and analytical development teams have built up proprietary technologies for client’s licenses and robust platform-based USP/DSP tailored to client’s manufacturing needs.
Our offer includes C> engineering discovery research and technology licenses, process and analytical development, DS and DP cGMP manufacturing, and testing services.
We adhere to strict control and assurance measures throughout to ensure we deliver exceptional quality products.
We adhere to strict control and assurance measures throughout to ensure we deliver exceptional quality products.
No Events
©2022 Porton Advanced Solution Ltd. All Rights Reserved. Instinctif Partners
Figure 8
Lentivirus titer produced in two suspension cell production system:
A. Viral titer from a leading commercial packaging system. B. Viral titer from Porton Advanced’s PTLV-SMART packaging system.
Figure 4
T cell transduction with lentivirus produced using our HEK293T system. T cells are infected with lentivirus at different MOI. CAR-T cell percentages were measured by FACS.
Figure 20
Figure 7
Figure 5
Figure 6
An AAV variant from our library screening showed that the virus was able to package a 6.1kb genome.
Figure 19
AAV variants enriched in different tissues during library screening. AAV libraries were prepared and injected into the hosts. After two weeks, tissues were harvested and viral genomes were isolated for PacBio sequencing. Viral genomes were clustered against different tissues.
Figure 18
Separation of empty and full rAAV by anion chromatography. A: AEX result of rAAV5; B: AEX result of rAAV9
Figure 3
CAR expression with escalated MOI using PTLV-SMART platform. Activated T cells transduced with escalated MOI, and FACS employed to demonstrate CAR expression post-7 days culture in G-Rex.
Figure 1
Time course of CAR transduction rates of CD3 T cells and cell viability during manufacturing in two cases. T-cells transduced with lentivirus analyzed by flow cytometry to detect CAR-positive or Protein L-positive cell ratio. T-cells expressed CAR stably in the period of CAR-T cell growth with high cell viability.
Figure 2